Literature DB >> 8996078

Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast.

E R Fisher1.   

Abstract

Management of ductal carcinoma in situ has become one of the most controversial topics in breast disease. While mastectomy has been the traditional treatment, many now feel it is excessive in most cases. As a result, a great effort has been made to identify pathobiological characteristics of DCIS that can be used to stratify appropriate treatment decisions. This article reviews efforts to relate pathobiological characteristics to disease management and provides treatment recommendations based on the latest evidence.

Entities:  

Mesh:

Year:  1997        PMID: 8996078     DOI: 10.3322/canjclin.47.1.52

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  4 in total

1.  Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: patterns of failure and 10-year results.

Authors:  L L Kestin; N S Goldstein; A A Martinez; M Rebner; M Balasubramaniam; R C Frazier; J T Register; J Pettinga; F A Vicini
Journal:  Ann Surg       Date:  2000-02       Impact factor: 12.969

2.  [TNM classification of breast cancer: changes and comments on the 7th edition].

Authors:  H-P Sinn; B Helmchen; C H Wittekind
Journal:  Pathologe       Date:  2010-09       Impact factor: 1.011

Review 3.  Microinvasive carcinoma of the breast.

Authors:  Simonetta Bianchi; Vania Vezzosi
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

4.  Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study.

Authors:  Serena Bertozzi; Carla Cedolini; Ambrogio P Londero; Barbara Baita; Francesco Giacomuzzi; Decio Capobianco; Marta Tortelli; Alessandro Uzzau; Laura Mariuzzi; Andrea Risaliti
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.